Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

13.97 -0.08 (-0.57%)
Streaming Delayed Price Updated: 9:30 AM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Teva Pharmaceutical Industries ADR

< Previous 1 2 3 4 5 6 Next >
Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhaler Use in Asthma and COPD
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims
From Teva Pharmaceutical Industries Limited
Via Business Wire
Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 2021 Showed AJOVY® (fremanezumab-vfrm) Injection Reduced More Monthly Migraine Days in a Network Meta-Analysis Study with Atogepant and Rimegepant
From Teva Pharmaceutical Industries Limited
Via Business Wire
Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache...
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) Tablets in Adult Patients with Tardive Dyskinesia
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Generic Medicines Saved the United States $28.8 Billion in 2020, and a Total of $43.1 Billion Across Major Markets, According to Independent Analysis
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reports Second Quarter 2021 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Changes to Executive Management Team
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Host Conference Call to Discuss Second Quarter 2021 Financial Results at 8 a.m. ET on July 28, 2021
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and Bioeq Announce Commercial Partnership for Biosimilar
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Ministry of Health, Labour and Welfare Approves AJOVY® (fremanezumab) Injection in Japan for the Preventive Treatment of Migraine in Adults
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Its Launch of the First Generic PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, Used to Treat Chronic Obstructive Pulmonary Disease (COPD), in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces the U.S. Launch of its Generic Version of SOOLANTRA® (ivermectin) Cream, 1% for Once Daily Treatment of Rosacea
From Teva Pharmaceutical Industries Limited
Via Business Wire
New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection Presented at 2021 American Headache Society (AHS) Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2021 American Headache Society (AHS) Annual Meeting, Showcasing Teva’s Longstanding Heritage in the Management of Migraine
From Teva Pharmaceutical Industries Limited
Via Business Wire
The Companies Tackling A Global Health Crisis
Via FinancialNewsMedia
Teva Announces the U.S. Launch of the First Generic Version of THIOLA® (tiopronin) tablets
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Highlight Research in Respiratory Care at Upcoming 2021 American Thoracic Society International Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Launch of its Generic Erythromycin Tablets USP, Used to Treat or Prevent a Variety of Bacterial Infections, in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at American Psychiatric Association Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces the Launch of the First Generic Version of Absorica® (isotretinoin) Capsules, for the Treatment of Severe Recalcitrant Nodular Acne in Patients 12 Years of Age and Older, in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reports First Quarter 2021 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Analyses of AUSTEDO® (deutetrabenazine) Tablets and Assessment of Schizophrenia Clinical Outcomes at Upcoming 2021 American Psychiatric Association Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Launch of its Generic Version of Canasa® (mesalamine) Suppositories To Treat Adults with Active Ulcerative Proctitis (ulcerative rectal colitis), in the United States
From Teva Pharmaceutical Industries Limited
Via Business Wire
New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Reduction of Migraine Burden Presented at 2021 American Academy of Neurology Virtual Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Analyses of AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets at Upcoming 2021 American Academy of Neurology Virtual Annual Meeting, Highlighting Teva’s Ongoing Commitment to Neurology
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults
From Teva Pharmaceuticals Industries Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.